Gerresheimer Opens New Development Center in China
Gerresheimer AG announced that it has opened a new development center for medical plastic systems in Dongguan City, China. The new Technical Competence Center (TCC) in China will be managing large-scale projects.
Gerresheimer AG announced that it has opened a new development center for medical plastic systems in Dongguan City, China. The new Technical Competence Center (TCC) in China will be managing large-scale projects.
“The new center in China ensures that we can optimally meet the growing demand in the Asian market,” said Andreas Schütte, member of Gerresheimer Management Board for Plastics & Devices, in a press release. Schütte added that the company plans to have development operations in addition to local production operations to enable closer collaboration with its customers in China.
The company currently has two other development centers in Wackersdorf, Germany and Peachtree City, US. Gerresheimer’s development centers produce medical plastic systems such as insulin pens, inhalers, lancets and auto-injectors for industrialization. All interdisciplinary functions up to a product’s series production stage are performed at these sites.
The local projects implemented at the development centers in collaboration with the other sites include series design, manufacturing equipment engineering, process development, project management, quality planning, tool making, automation technology, production initiation and pre-series production.
At its Dongguan City production facility, Gerresheimer has been manufacturing drug delivery devices such as inhalers and lancets for diabetes sufferers, and infusion products, since 2006.
Source: Gerresheimer
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
